

# Index

## Notes

Entries involving the term 2D and 3D are sorted under the subsequent word e.g.

'3D applications' is alphabetized under A.

Page numbers ending in f refer to figures and those ending in t to tables.

## A

Abdominal CT 122, 187  
 Abscess, Crohn disease 128  
 Accommodation disorders 19  
 ACRIN trial no. 6664 182  
 Additional 3D projections 52–53  
 Adenocarcinoma 110  
 Adenoma 101, 177  
   advanced 95, 178f, 180–181  
   cecum 131, 131f  
   ileocecal valve 132, 133f  
 Adenoma–carcinoma sequence 95, 96f, 179f  
 Adenomatous polyps 95–96, 97t, 137, 177  
 Advanced 3D visualization techniques 51t, 58–61, 90, 90f  
   distortion 60, 61f  
   practical usefulness 60–61  
 Advanced adenoma 95, 178f, 180–181  
 Air  
   colon distension 21, 27  
   intramural 37–38  
 Air bubbles 148–149, 149f  
 Allergic reactions 16  
 American Cancer Society (ACS) screening guidelines 5, 182, 183t  
 American College of Radiology (ACR) recommendations 159, 182  
 American Gastroenterological Association (AGA) reporting guidelines 173–174, 173t  
   diminutive polyps 174  
   polypectomy 174  
   small/medium-sized polyps 173–174  
 Anal papillae, hypertrophic (anal polyp) 153  
 Anal polyp (hypertrophic anal papillae) 153  
 Aneurysmal dilation 120  
 Annular tumors 112, 112f, 113f, 115f  
 Antispasmodic agents 19–20, 19f, 40, 117, 151  
   ESGAR consensus statement 19, 20t  
   see also individual agents  
 Aortic aneurysm, abdominal 156f  
 Appendiceal stump, inverted 130–131, 130f, 152  
 Appendicitis 133–134  
 Appendix 85, 85f, 130  
   mucocele 132–133, 133f, 134f  
   neoplastic changes 132–134, 133f, 134f

3D Applications 52–61  
 Artifacts 80, 140–154, 141t, 173  
   digital subtraction 54–55, 55f  
   technical errors 141–142  
   see also individual artifacts  
 Ascending colon 79f, 80f, 82, 85  
 Automation bias, CAD 71  
 Axial images, 2D 43–44  
   collimation 43  
   colonic distension 44  
   internal structure evaluation 44  
   prone-supine image correlation 44, 45f  
   slice thickness 43  
   suboptimal bowel preparation 44  
   window settings 44, 45f

## B

Backwash ileitis (pancolitis) 124  
 Barium 13–15, 36  
   iodinated contrast media and 16–17  
   laxative-free CT colonography 18  
   residual 13, 15, 15f, 146  
   sedimentation 15, 15f  
 Barium coating 15, 15f  
 Barium enema 183t, 191  
 Beam-hardening artifacts 104, 142, 142f, 149–150, 150f  
 Biopsy, deep 2, 39  
 Bisacodyl 11, 12–13  
 Bladder carcinoma 156f  
 Blind spots 47, 48f, 56, 56f, 145  
   advanced 3D visualization techniques 58  
 "Blue puffer" (manual insufflation bulb) 21, 22f  
 Bowel preparation protocols 9–13  
   colorectal cancer screening 183  
   combination 12  
   ESGAR consensus statement 18  
   modified 9  
   "wet" preparation 11–12  
 Bowel purgation 10–13  
 Bowel segments 82–86  
   collapsed see Collapsed bowel segments  
   distension and 82–86  
 Bowel wall 79–82

- characteristics 81–82, 82f
  - colorectal lymphoma 120, 120f
  - Crohn disease 126–127, 129
  - diagnostic criteria 81–82
  - inflammatory bowel disease 121, 122f
  - inflammatory stenosis 117, 117f
  - mobility 82
  - thickness 81–82, 81f, 82f
  - ulcerative colitis 124, 125, 126
  - Bronchial carcinoma 156f
  - Buscopan (butylscopolamine) 19–20
  - Butylscopolamine (Buscopan) 19–20
- C**
- Carbon dioxide 21, 27
  - Carcinoids 107, 134
  - Carcinomas 92f, 132, 132f
    - appendix 134, 134f
    - computer-assisted detection 70, 71f, 73
  - Carpet lesions 101
  - Cecum 79f, 80f, 85–86, 85f
    - 3D evaluation 50
    - distension 83
    - flat lesions 103f, 130
    - neoplastic changes 131, 131f, 132f
  - Clear liquid diets 9–10
  - Collapsed bowel segments 118, 119f, 143–144
    - colorectal carcinoma vs. 118, 119f
    - interpretational errors 119f, 150
  - Collimation 28–29, 32, 43
  - Colon 79–87
    - anatomical landmarks 79, 79f, 80f
    - ascending 79f, 82, 85
    - descending 38f, 79f, 80f, 84f, 85
    - elongated 2f, 86f, 87
    - external compression 154
    - external tumor infiltration 109f, 117, 118f
    - extrinsic lesions 154, 155f
    - intrinsic lesions 150–153
    - length variations 86–87
    - lesion measurement 51t
    - lymphatic drainage 116
    - malignant diseases 110–121
    - metachronous lesions 138f, 139
    - perforation see Perforation
    - positional anomalies 87, 87f
    - sigmoid see Sigmoid colon
    - stenosis 154, 155f
    - transverse see Transverse colon
    - wall see Bowel wall
  - Colon distension 18–28
    - 2D axial images 44
    - adequate 21, 25, 27
    - automatic 22–23, 22f, 23f
    - colorectal cancer screening 183
    - colostomy 139
    - contraindications 2
    - CT scout image 25–26, 26f
    - evaluation strategy choice 51
    - first scan 27
    - gas choice 20t, 21
    - inadequate 22, 23f
    - manual 21–22, 151
    - patient aftercare 28
    - patient information 19
    - patient positioning/repositioning 26, 26f
    - perception errors 143–144, 144f
    - preparation 19–21, 25
    - principles 19–21
    - second scan 27–28
    - segments and 82–86
    - technique 20t, 21–23, 27–28
  - Colonic anastomoses 135–139, 136f, 137f
    - benign ulceration 137
    - diagnostic criteria 140
    - protruding suture materials 136–137, 137f
    - tumor recurrence 138–139, 138f
  - Colonic flexures 44
  - Colonic folds 150, 151f
  - Colonic mass 62
  - Colonic resection 135
  - Colonic stents 139–140, 139f, 140f
  - Colonoscopy
    - colorectal carcinoma 110, 179, 180, 183t
    - contraindications 3–4, 3f
    - incomplete 1–2
    - polyp measurement 65, 66f
    - postoperative 4, 135
    - refusal to undergo 3–4
    - as screening procedure 182
    - ulcerative colitis 5, 126
  - Colorectal carcinoma 110–119
    - CT colonography 2–3, 3f, 110–111
      - criteria 111–114
      - indications 111
      - limitations 111
      - optical colonoscopy vs. 110
      - postoperative surveillance 135
      - screening 180–184, 181f
      - sensitivity 110
    - diagnostic criteria 118–119
    - differential diagnosis 117–118
    - distribution 110, 110f
    - diverticulitis vs. 117, 117–f, 118t, 122
    - documentation 111t
    - epidemiology 177
    - fecal tagging 119
    - hematogenous metastasis 116, 116f
    - intravenous contrast 33, 33f, 112f, 113, 119
    - lymph node involvement 111, 115–116, 116f
    - metastases 114, 116, 139
    - moderate risk level 5

- morphology 111–112, 113, 118
- M staging 115–116
- N staging 114, 115–116
- positional mobility 113–114, 119
- postoperative surveillance 4, 135–140
- prestenotic colon evaluation 116
- recurrence 135
- saddle-shaped 112, 112f
- screening 5–6, 177–185
  - procedure choice 179–184
  - requirements 177–179, 178f
- spasms vs. 151
- staging 114–116
- stenotic 2–3, 112f
- structure 112f, 113, 113f
- surgical intervention 111
- T staging 114–115, 114f, 115f, 118
- Colorectal lymphoma 119–121
  - diagnostic criteria 121
  - differential diagnosis 120–121
  - diffuse form 120
  - focal forms 120
  - infiltrative mass 120, 120f
  - morphology 120, 121
  - secondary findings 120, 121f
  - symptoms 119
- Colostomy 37, 37f, 139
- Combined 2D/3D views 53, 53f
- Comb sign 127
- Complete rim sign 88
- Computer-assisted detection (CAD) 66–75
  - algorithms 66, 66f, 67, 74
  - bowel preparation 70, 70f
  - calculation 73
  - carcinomas 70, 71f, 73
  - closed systems 67
  - as concurrent reader 72, 72f
  - examination protocols 70
  - extracolonic involvement 70, 71f, 72, 73
  - false-positive findings 70–71, 74, 74f
  - fecal tagging 70
  - as first reader 71–72
  - flat lesions 70, 74
  - future perspectives 74–75
  - interpretation strategies 71–73, 74
  - interpretation time, influence on 73–74
  - modifiable systems 67–69
  - nonpolypoid lesions 72, 74
  - patient populations 69
  - performance influencing factors 70–71
  - pitfalls 141t
  - polyps 66–75
  - principles 66–69, 74t
  - procedure 66–67
    - candidate polyps 67, 67f
    - presentation to radiologist 67, 68f
    - segmentation 66–67
  - as second reader 72–73, 72f
  - settings 67–69
  - software system comparability 69
  - sphericity 69, 69f
  - as training method 190, 190f
  - true-positive results 74
  - use in practice 70–71
- Coned-down views (3D target views) 53, 54f
- Conglomerate masses, Crohn disease 128
- Contrast media
  - dual-energy CT colonography 31
  - intravenous see Intravenous contrast media
  - iodinated 15–16, 15f, 34
  - nonionic 12
  - nonionic iodinated 16
- C-RADS (CT Colonography Reporting and Data System) 169–173
  - colonic lesions categories 169–172, 170f, 170t, 171f, 172f
  - colonic lesions morphological description 169, 169t
  - controversies 174
  - diminutive polyps recommendations 105
  - extracolonic findings 157, 172–173, 173t
  - findings classification 169–172
  - lesion size 169, 174
  - polypectomy vs. surgery 169–172
  - polyp measurement 62
  - recommended follow-up 169–172
- Crohn disease 126–129
  - advanced disease 127–128, 128f
  - cobblestone pattern 127–128, 128f, 142
  - complications 128, 129f
  - diagnostic criteria 129
  - fecal tagging 129
  - inflammatory restenosis 138f, 139
  - intravenous contrast media 34f, 129
  - perforation 128, 129
  - stenoses 117f, 128, 129f
- CT colonography
  - abdominal CT vs. 187
  - cardiovascular effects 40
  - collimation 28–29, 32
  - compliance 180
  - complications 180
  - contraindications 4, 6–7, 7t, 39, 121
  - diagnostic 1–5, 1t
  - difficulty 191
  - dose modulation 31, 32
  - dose reduction 30–31
  - dual-energy 31–32, 32f
  - evaluation see Evaluation
  - examination 9–42
  - extracolonic findings see Extracolonic findings
  - findings 79–164
  - historical aspects 28
  - image interpretation 43–77
  - indications 1–8, 1t

laxative-free 18  
 mistakes, lack of expertise 188, 188f  
 patient age and 3–4  
 patient preparation 9–18  
 pitfalls see Pitfalls  
 radiation exposure 30–31, 40  
 reconstruction parameters 30t  
 risk profile 36–40  
 scan direction 29  
 as screening procedure 1t, 5–6, 180–184  
   costs coverage 183  
   current recommendations 182–183, 183t  
   extracolonic findings 182  
   optical colonoscopy vs. 182  
   recent literature results 181–182  
   sensitivity 181, 182  
   technical aspects 183–184  
 steps 9  
 technique 28–40  
 training see Training  
 tube current reduction 30–31  
 tumor induction 40  
 CT scout image 22, 23, 26f, 27–28  
 Cystadenocarcinoma, appendix 133, 134  
 Cystadenoma, appendix 133, 134

## D

Data analysis 43–52  
 Databases 189f, 189t, 190  
 Descending colon 38f, 79f, 80f, 84f, 85  
 Diatrizoate 15–16, 18  
 Diets  
   clear liquid 9–10  
   low-residue 9–10  
 Digital rectal examination 27  
 Digital subtraction 18, 54–55, 55f  
   artifacts 54–55, 55f  
   incomplete 55, 56f  
   partial volume effects 55  
 Diminutive polyps 104–105, 104f, 105f, 174  
   inaccurate measurement 64  
   malignant transformation 177, 178f  
   stool vs. 104  
 Diverticula 88, 88f, 91  
   air-filled 122  
   impacted see Impacted diverticula  
   interpretational errors 152  
   inverted 88  
   orifice 152  
   sessile polyps vs. 98, 99f, 152  
 Diverticular disease 5, 83–85, 84f, 87–91  
   morphology 88–90  
   pathogenesis 88  
 Diverticulitis 122–123  
   acute 122

  chronic 122, 123, 123f  
   colorectal carcinoma vs. 117, 117f, 118t, 122  
   complications 122, 123f  
   diagnostic criteria 123  
   differential diagnosis 117f, 122  
   indications/contraindications 122  
   morphology 80, 122, 123, 123f  
   perforation 122, 122f  
 Diverticulosis 89–90, 89f, 90f, 91  
 Documentation see Reports/reporting  
 Dolichocolon (elongated colon) 2f, 86f, 87  
 Dose length product (DLP) 31  
 Doughnut sign 150–151, 151f  
 Drug-induced reactions 40  
 Dry bowel preparation (“dry prep”) 10  
 Dual-energy CT colonography 31–32, 32f

## E

Elderly patients 3, 4f, 158  
 Electronic cleansing see Digital subtraction  
 Electronic labeling 54, 54f  
 Elongated colon 2f, 86f, 87  
 Endo-eccentric mass 120  
 3D Endoluminal view 47–49, 50  
   2D techniques vs. 47  
   2D view correlation 49, 49f  
   applications 49  
   bidirectional evaluation 47–48, 48f  
   blind spots 47, 48f  
   colorectal structure interpretation 47, 48f  
   differentiation 47  
   diverticulosis 90, 90f  
   inflammatory bowel disease 122  
   intraluminal navigation 47  
   polyp display time 46f, 47, 48f  
   prone and supine position correlation 49  
   slice thickness 47  
   specificity 49f  
   viewing angle 47, 47f  
   well-cleansed bowel 51  
 Endometriosis 108, 109f  
 Endoscopy, flat lesions 101, 102f  
 End-to-side anastomoses 135–136, 137f  
 ESGAR consensus statement  
   antispasmodic agents 19, 20t  
   bowel preparation 18  
   colon distension 20t, 21  
   colonic lesion documentation 168–169  
   datasets analysis 50, 51t  
   extracolonic findings reporting recommendation 159  
   patient positioning 20t, 23  
   polyps 62–63, 169  
   practical recommendations 32  
   rectal catheters 20, 20t

- European Society of Gastrointestinal and Abdominal Radiology (ESGAR)  
 consensus statement see ESGAR consensus statement  
 diminutive polyps recommendations 104–105  
 workshops 188, 189f
- Evaluation  
 2D 43–46, 49–50  
 complex pathologies 51  
 disadvantages 46  
 inflammatory bowel disease 122  
 mobility/immobility assessment 50  
 polyp display time 46, 46f  
 poor distension 51  
 primary 49–50  
 reduced bowel preparation 51, 52f  
 residual material 51  
 window setting pitfalls 143  
 2D vs. 3D 47, 49f  
 3D 47–49, 50  
 bidirectional 50  
 performing 50, 50f  
 bowel preparation 51, 52f  
 combined 2D/3D 46f, 50  
 complex pathologies 51  
 distension and 51  
 endoluminal views see 3D Endoluminal view  
 fecal tagging 51, 52f  
 performing 49–52  
 residual material 51  
 strategy choice 51–52, 51t  
 Evaluation time 52
- Extracolonic compression 108, 109f
- Extracolonic findings 155–159, 159t, 182  
 classification 155–157  
 clinical relevance 155t, 156, 156f, 157f  
 computer-assisted detection 72, 73  
 controversial aspects 158  
 C-RADS 157, 172–173, 173t  
 detection/differentiation improvement 158–159, 159f  
 diagnostic CT colonography 158  
 distribution 157–158  
 examination technique and 158  
 frequency 157–158  
 intravenous contrast media 33–34, 34f  
 malignancy 155  
 patient populations 158  
 reporting 159, 166, 169  
 screening studies 158
- E-Z-CT 14
- F**
- Familial adenomatous polypos (FAP) 105–106, 105f
- Fecal immunochemical tests 179
- Fecaliths 88
- Fecal occult blood test 179–180
- Fecal tagging 13–17, 35–36  
 administration principles 13  
 colorectal cancer 113, 113f, 119, 183  
 colorectal lymphoma 121  
 combined protocol 16–17  
 computer-assisted detection 70  
 Crohn disease 129  
 definition 13  
 diagnostic CT colonography 30t  
 digital subtraction 54  
 diverticulosis 90f  
 evaluation strategy 51, 52f  
 flat lesions 103–104, 103f  
 foam 147–148, 148f  
 high density 149–150  
 inadequate 149, 149f  
 inflammatory bowel disease 121  
 interpretational errors 149–150  
 intravenous contrast media and 35, 36, 36f  
 intravenous contrast media vs. 33, 34  
 lipomas 106, 107  
 modified protocols 16  
 mucosal polyps 101  
 pedunculated polyps 100, 101f  
 polyethylene glycol preparations and 11  
 polyp detection 13, 13f, 70, 144, 145f  
 polyp measurement 65  
 polypoid filling defects, extracolonic origin 110  
 polypoid lesions 93t  
 post-incomplete colonoscopy 2  
 protocols 9, 13  
 reduced bowel preparation 17  
 residual matter 145  
 screening CT colonography 30t  
 sedimentation 149  
 sessile polyps 99, 99f  
 stool particles 145, 146, 149  
 translucency rendering 57f, 58  
 ulcerative colitis 126  
 untagged stool with 149, 150f
- Fibrofatty proliferation, Crohn disease 127
- Filet view 59–60, 60f
- Findings, extracolonic see Extracolonic findings
- Fish-eye effect 47
- Fistulae 123f, 128, 129f
- Flat lesions 101–104  
 3D views 102, 103f  
 categorization 102  
 cecum 130  
 cigar-shaped appearance 103, 103f, 104  
 computer-assisted detection 70, 74  
 contrast media 33, 103, 104  
 definitions 101, 102f  
 detectability 102, 102f  
 diagnostic criteria 104  
 endoscopy 101, 102f  
 fecal tagging 102, 103–104, 103f

histology 101  
 incidence 102  
 inner structure 103–104, 103f  
 malignant potential 102  
 measurement 62, 63f, 64  
 mobility 103–104  
 morphology 91f, 92f, 102–103, 104, 166  
 on semilunar fold 103  
 stool particle vs. 131, 131f  
 window settings 44

Fleet Kit 10

Flexural pseudotumor 81f, 150, 188f

Fluid droplets 147–148

Fluid tagging 13–17

“Fly-throughs” 43

Foam 147–148, 148f

Focal diverticulitis (inflammatory pseudotumor) 122–123, 124f

Focal nodular hyperplasia 157f

Free-floating polyps 147, 148, 148f

## G

Gallstones 157–f

Gas

for colon distension 20t

redistribution 24f, 25f

Gas bubbles 148–149

Gastric cancer 117

Gastrografin 18

Gastrointestinal stromal tumor 107, 108f

Global views (3D maps) 53, 53f, 122, 123f, 152

Glucagon 20

## H

Haustra 80, 80f, 81f, 125, 126f

Hemicolectomy 135

Hemorrhoids, internal 153, 154f

Hernia, incisional 37f

Hip prostheses 142, 142f

Houston valves 83

Hyperplastic (inflammatory) polyps 96, 137

Hypertrophic anal papillae (anal polyp) 153

## I

Ileocecal region 130–134

inflammatory changes 134

misinterpretation 130

neoplastic changes 131–134

postoperative findings 130–131

Ileocecal valve 50, 85–86, 86f, 130

configuration 85, 86f

interpretational errors 152–153, 154f

lipomatous 86, 86f, 132, 132f

neoplastic changes 132, 132f

polyps vs. 85

Image noise 82, 83f, 142

Impacted diverticula 88–89, 89f, 91

interpretational errors 152, 153f

translucency rendering 58

Incisional hernia 37f

Incomplete rim sign 98

Inflammatory bowel disease(s) 5, 5f, 121–129

bowel wall thickening 121, 122f

chronic 5, 123–129

examination technique 121–122

fecal tagging 121

imaging indications/contraindications 5, 121, 123

intravenous contrast media 33, 34f, 122

morphology 122

see also individual diseases

Inflammatory (hyperplastic) polyps 96, 137

Inflammatory pseudopolyps 125, 126f

Inflammatory pseudotumor (focal diverticulitis) 124f

Inflammatory restenosis 138f, 139

Inflammatory stenosis 117, 117f, 118t

Insufflators 22–23, 22f

Internal data transmission system 29

Intra-abdominal mass 108

Intraluminal air cast 53

Intramural pneumatosis 37–38, 38f

Intravenous contrast media 32–36, 33f, 34f

adverse effects 34

bowel wall 82

colorectal tumors 112f, 113, 119, 121

contraindications 34

controversy over 32

Crohn disease 129

dosage 34

effects 33

extracolonic involvement 33–34, 34f

fecal tagging and 35, 36, 36f

fecal tagging vs. 33, 34

flat lesions 103, 104

indications 34

inflammatory bowel disease 122

intracolonic lesions 33

late arterial phase 35, 35f

lipomas 107

misinterpretation 35

mucosal polyps 101

“one-stop” shopping protocol 35

polypoid filling defects, extracolonic origin 110

polypoid lesions 93t

residual stool 145, 146

saline chaser 35

scan delay 34–35

for second scan 34

technique 34–36

ulcerative colitis 124, 126  
 venous phase 35  
 Inversion ligation 131  
 Inverted appendiceal stump 130–131, 130f, 152  
 Inverted diverticulum 88  
 Iodine map 31

## K

Kissing folds 80  
 Klean-Prep 11, 12  
 Kohlrausch fold 83, 83f

## L

Laceration 37–38, 38f  
 Laxative-free CT colonography 18  
 Laxatives 10–13, 17  
   inadequate preparation 10f, 11f  
   see also individual drugs  
 Left colonic flexure 85  
 Linear artifacts 55  
 -linear artifacts 55f  
 Lipoma(s) 93f, 106–107, 106f, 170, 171f  
   diagnostic criteria 107  
   fecal tagging 106, 107  
   ileocecal valve 132, 132f  
   internal structure 106  
   mobility 106–107  
   morphology 106, 107  
   translucency rendering 57f, 58  
   treatment 107  
 Liver hemangiomas 157f  
 LoSo Prep Kit 12  
 Low-residue diets 9–10  
 Lumen tracking 43–44, 44f, 46, 49  
 Lymphadenopathy 119, 121f  
 Lymph nodes 116  
 Lymphoma  
   colorectal see Colorectal lymphoma  
   submucosal 107, 107f

## M

Magnesium citrate 12  
 Malignant lymphomatous polyposis 120, 121  
 Manual insufflation bulb (“blue puffer”) 21, 22f  
 3D Maps (global views) 53, 53f, 122, 123f, 152  
 Mass, intraluminal 120  
 Megacolon, toxic 124, 125f  
 Metachronous lesions 138f, 139  
 Metal artifacts 142, 142f  
 Metastases, distant 139  
 Minimal prep (prepress) protocols 9, 54

Movement artifacts 28  
 Moviprep 11  
 Mucocele, appendix 132–133, 133f, 134f  
 Mucosal painting 48f, 56, 56f  
 Mucosal polyps 95–106  
   CT colonography, current status 96–97  
   detection rates 96–97, 97t  
   diagnostic criteria 100–101  
   macroscopic criteria 96  
   mobility 101  
   morphology 100, 101  
   study results 96–97  
 Mucus 147, 148f  
 Multidetector CT 28  
 Multidetector CT colonography  
   data volume 29–30  
   ESGAR consensus statement 32  
   protocols 28–32, 30t  
   reconstruction increment 29–30  
   scanning parameters 29t, 30t  
 2D Multiplanar reformation (2D-MPR) 45–46, 46f  
 Munich Colon Cancer Prevention Trial 182

## N

Narrow (soft-tissue) window settings 44, 45f, 143  
 National Cancer Institute (NCI) database 190  
 Nitrogen 21  
 Nonadenomatous polyps 96  
 Noncontrast scans 35–36  
 Non-Hodgkin lymphoma 121f  
 Nonpolypoid lesions, CAD 74  
 NutraPrep 17

## O

Optical colonoscopy see Colonoscopy  
 Ovoid polyps 62, 63f, 64f

## P

Pancolitis (backwash ileitis) 124  
 Panoramic view 58–59, 58f, 59f, 60  
 Partial volume effects (averaging) 28, 29f, 55  
 Patient positioning 23–25, 27  
   additional CT scans 25, 26f  
   ESGAR consensus statement 20t, 23  
   first scan 27  
   intravenous contrast agent administration 24  
   positioning aids 25  
   prone position 25  
   right/left decubitus position 25, 25f  
   sequence of positions 23–24  
 Patient repositioning 23, 24f, 27



- Pedunculated polyps 100, 172f  
 fecal tagging 100, 101f  
 internal structure 100  
 measurement 62, 62f, 64f  
 mobility 93f, 100, 100f, 101, 151  
 morphology 91f, 92f, 100, 100f, 166  
 pseudomobility 92, 100  
 translucency rendering 57
- Perforation 36–40  
 complete 39  
 contained 39, 39f  
 Crohn disease 128, 129  
 diverticulitis 122, 122f  
 intraperitoneal segments 37  
 morphology 37–39  
 procedure after 40  
 rates 36–37, 180  
 retroperitoneal segments 37  
 risk factors 37, 37f  
 risk reduction 39–40  
 surgical intervention 40  
 ulcerative colitis 124–125  
 wide window setting 37, 38f
- Pericolonic fat stranding 115, 117
- Peritoneal carcinosis 109f, 117, 118f
- Phosphate nephropathy 11
- Phospho-soda (sodium hydrogen phosphate) 10–11, 11f
- Picolax (sodium picosulfate) 10, 12
- Picture archiving and communication system (PACS) 29
- Pitfalls 140–154, 141t, 187  
 CT scanning 141–142  
 data evaluation 142–145  
 data interpretation 141t  
 evaluation technique 143  
 interpretational errors 145–154  
 perception errors 141t, 143–145  
 reading errors 143  
 technical errors 141–142, 141t
- Plicae semicirculares see Semilunar folds
- Pneumatosis cystoides coli 107, 107f
- Polyethylene glycol (PEG) 10, 11–12
- Polyp(s) 4–5, 94–107  
 CAD see Computer-assisted detection (CAD)  
 definition 94  
 detection 6, 6f  
 diagnostic criteria 100–101  
 diverticula vs. 99f, 155  
 fecal tagging 13, 13f  
 ileocecal valve 132, 133f  
 inflammatory (hyperplastic) 96, 137  
 intravenous contrast media 33, 33f, 35f  
 lumen tracking 44  
 measurement see Polyp measurement  
 morphology 145, 166  
 mucus vs. 147  
 perception 143  
 prestenotic colon 116  
 redistribution, position changes 24f, 25f  
 reporting 166, 169  
 stool particle vs. 145, 146f  
 surveillance 4–5  
 translucency rendering 57f  
 volume measurement 64–65, 65f  
 see also individual types
- Polyp display time 46, 46f, 47, 48f
- Polypectomy 2, 39, 174, 179  
 postoperative findings 152, 153f
- Polyp measurement 62–66, 166  
 correct measurement criteria 62  
 CT colonography vs. optical colonoscopy 65–66  
 fecal tagging influences 65  
 on semilunar folds 64, 65f  
 techniques 62–65  
 automated 63–64, 64f, 65f  
 manual 62–63, 63f, 64f  
 window settings 44, 45f, 62–63, 63f
- Polypoid artifacts 55
- Polypoid filling defects 108–110, 138
- Polypoid lesions 91–110  
 3D evaluation 91, 92f  
 contrast uptake 91, 92f, 93t  
 CT colonography characterization 91–94, 93t  
 extracolonic origin 108–110, 109f  
 fecal tagging 93t  
 internal structure 91, 92f, 93f, 93t, 94f  
 mobility 91–94, 93f, 93t, 94f  
 morphology 91, 91f, 93t, 94f  
 pseudomobility 92  
 supine-prone position correlation 94, 95f  
 translucency rendering 56–57, 57f, 91
- Polypoid tumors 111, 111f, 113f
- Prediverticulosis 87f, 88
- Prepacol 10, 12
- “Prepress” (“minimal prep”) protocols 9, 54
- PROTOCOL<sub>2</sub>L 22, 22f
- Pseudodiverticula 88
- Pseudoenhancement 65, 149–150, 150f
- Pseudolesions 55
- Pseudomobility, polyps 92, 99, 100, 100f  
 interpretational errors 93f, 151–152
- Pseudopolypoid lesions 74, 74f, 127–128
- Pseudopolyps, inflammatory 125, 126f
- Pseudostenosis 117

## R

- Reading paradigm 51t
- Rectal catheters 20–21, 27  
 balloon inflation 20–21, 27  
 colorectal carcinoma 114, 114f  
 complications 21  
 ESGAR consensus statement 20, 20t  
 perforation 37, 37f, 39



- types 20, 21f
  - Rectal varices 153, 154f
  - Rectosigmoid junction 80f
  - Rectum 79–87, 79f
    - anatomy 83, 83f
    - distension 83
    - evaluation 49, 50, 50f, 83
    - flat lesions 103f
    - lymphatic drainage 116
    - malignant diseases 110–121
    - transverse folds (Houston valves) 83
  - Reduced bowel preparation 3, 4f, 17, 17f
  - Redundant colon (elongated colon) 2f, 86f, 87
  - Renal cell carcinoma 156f
  - Reports/reporting 165–175
    - components 165–168
    - controversies 174–175
    - examination technique 168
    - findings 165–166, 168
      - colonic 166
      - documentation 168–174
      - examination completeness 165–166
      - extracolonic 159, 165, 169
      - lesion description 166
      - standardization strategies 168–174
    - generation 165–175
    - images 167f, 168
    - impression 166, 168
    - indication 165
    - limitations disclaimer 166
    - quality statement 165–166
    - recommendations 166, 168
    - semiautomated 167f, 168
    - technical description 165
  - Residual fluid 49, 51
    - marking 13–17
    - redistribution, position changes 24f, 25, 25f
    - untagged 144, 144f
  - Residual matter, interpretational errors 145–154
  - Respiration artifacts 28, 29, 141, 141f
- S**
- Scan C barium suspension 14
  - Scannostrast 14
  - Screening window 177
  - Seeds 147, 147f
  - Segmental spasm 117, 119f
  - Semiannular tumors 111–112, 112f
  - Semilunar folds 80, 80f, 81f
    - 3D evaluation 50
    - artifacts 80
    - concertina appearance 87f, 88
    - diverticulitis 80
    - flat lesions 103
    - polyp measurement inaccuracies 64, 65f
    - prediverticulosis 87f, 88
    - ulcerative colitis 125, 126f
  - Serrated adenomas 96
  - Sessile polyps 98–99, 171f
    - cecum 131f
    - contrast coatings 99, 99f
    - diverticula vs. 98, 99f
    - fecal tagging 99, 99f
    - internal structure 98–99, 99f
    - measurement 62, 62f
    - mobile bowel segments 99
    - mobility 93f, 99, 101
    - morphology 91f, 92f, 94f, 98, 98f, 131, 166
    - panoramic view 59f
    - pseudomobility 99, 100f
  - Shape index 67f
  - “Shared memory” 29
  - Shine-through artifacts 143, 143f
  - Shoulder formation 111, 118
  - Sigmoid colon 79f, 83–85, 84f
    - axial 2D views 80f
    - diminutive polyps 104f
    - distension 83
    - diverticular disease 83–85, 84f
    - diverticulosis 90f
    - elongated 84f, 87
    - endometriosis 109f
    - haustation 83, 84f
  - Sigmoidoscopy 180, 183t
  - Sigmoid stoma 139
  - Skip lesions 126, 127f, 129
  - Slice thickness 28–30, 29f, 43, 47
    - soft-tissue contrast improvement 158, 159f
  - Sodium hydrogen phosphate (Phospho-soda) 10–11, 11f
  - Sodium picosulfate (Picolax) 10, 12
  - Soft-tissue (narrow) windows 44, 45f, 143
  - Spasmolytics see Antispasmodic agents
  - Spasms 150–151, 151f, 152f
  - Stairstep artifact 28, 47, 141–142, 142f
  - Stenosing carcinoma 119f
  - Stenosis 108
    - inflammatory 117, 117f
    - neoplastic 117, 117f
  - Stenotic lesions 117–118, 117f
  - Stool
    - 3D endoluminal views 49
    - diagnostic criteria 146
    - flat lesions vs. 131, 131f
    - interpretation errors 23
    - labeled (tagged) 149
    - mobility 145, 146
    - patient positioning 23, 24f, 25
    - polypoid 145, 146f
    - translucency rendering 57–58, 57f
    - untagged 145–146, 146f, 149, 150f
  - Stool marking see Fecal tagging
  - Submerged lesions 51, 52f, 149

Submucosal lesions 107, 107f, 108f  
 Submucosal polyps 106–107, 106f  
 Synchronous cancers 110, 116, 139

## T

Tablets 147, 147f  
 Taeniae 80, 80f, 85  
 Tagitol V 14  
 3D Target views (coned-down views) 53, 54f  
 Telebrix Gastro 18  
 Terminal ileitis 134, 134f  
 Tissue transition projection (TTP) 53  
 3D Tools 52, 54–58  
 Toxic megacolon 124, 125f  
 Training 187–191, 189t  
   acquired knowledge testing 190–191  
   colon as complex organ 187  
   database use 189f, 190  
   individual factors 191  
   practical experience 188–190  
   proven case interpretation 190–191  
   specialized 188–190  
 Translucency rendering 56–58, 57f  
   density 56  
   homogeneity 56  
   impacted diverticula 58  
   lipomas 57f, 58  
   polypoid lesions 56–57, 57f, 91  
   stool 57–58, 57f  
   usefulness 56  
 Transverse colon 46, 79f, 84f, 85  
   2D evaluation 50, 80f  
   distension 83, 85  
   elongated 87  
   flat lesions 103f  
 Triradiate fold 85  
 Tubular adenomas 95  
 Tubulovillous adenoma 95–96  
 Tumor infiltration 108, 109f, 118f

## U

Ulcerative colitis 5, 124–126  
   acute 124  
   advanced disease 124, 125f  
   bowel wall perforation 124–125  
   carcinoma risk 126, 127f  
   chronic disease 125  
   complications 124–125  
   contraindications 125, 125f  
   diagnostic criteria 126  
   early-stage disease 124  
   endoluminal 3D views 124, 125, 126f  
   fecal tagging 126  
   intravenous contrast 124, 126  
   “lead-pipe appearance” 124, 125  
   pericolonic 2D changes 125  
   subacute 125  
   surveillance 126  
 Undistorted bisegmentation view 60, 60f  
 Unfolded cube view 58, 58f, 59f, 60–61  
 Uterine fibroid 109f

## V

Villous adenomas 96  
 Virtual colonoscopy see 3D Endoluminal view  
 Virtual dissection 59–60, 59f, 60f, 61f, 90f  
   practical usefulness 61  
 Volume CT dose index (CTDIvol) 31

## W

Wet preparations (“wet prep”) 11–12  
 Wide window settings 37, 38f, 44, 45f, 143, 147  
 Working Group on Virtual Colonoscopy 169  
 Workshops 188, 189f, 190